The tumor growth inhibition rates for ICAM‐1‐Dxd at dosages of 1, 5, and 10 mg kg−1 were 51.3%, 93.6%, and 97.8% greater, respectively, compared to the PBS control group (Figure S19‐S21, Supporting Information). Here, ICAM1 is linked to neoplasm.